Background Therapeutic drug monitoring (TDM) in inflammatory bowel disease (IBD)
patients receiving anti‐tumour necrosis factor (TNF) agents can help optimise outcomes …

Background Nonresponse and loss of response to anti‐TNF therapies in Crohn's disease
represent significant clinical problems for which clear management guidelines are lacking …

Background: The contemporary management of ambulatory ulcerative colitis (UC) continues
to be challenging with∼ 20% of children needing a colectomy within childhood years. We …

Background & Aims Infliximab, a tumor necrosis factor antagonist, is effective for treating
patients with Crohn's disease (CD) and ulcerative colitis (UC). We aimed to determine …

Objectives To compare the pharmacokinetics (PK), safety and efficacy of innovator infliximab
(INX) and CT-P13, a biosimilar to INX, in patients with active ankylosing spondylitis (AS) …

Crohn's disease and ulcerative colitis are chronic inflammatory disorders resulting from
immune dysregulation. Patients who fail conventional medical therapy require biological …

Background & Aims We analyzed data collected during the Active Ulcerative Colitis Trials
(ACT-1 and ACT-2) to assess relationships between serum concentrations of infliximab and …

Background Infliximab (IFX) is effective therapy for ulcerative colitis and Crohn's disease, but
it may be associated with side effects and loss of response. One loss of response …

A growing number of population pharmacokinetic analyses of therapeutic monoclonal
antibodies (mAbs) have been published in the scientific literature. The aims of this article are …

Background Vedolizumab, an anti‐α4β7 integrin monoclonal antibody (mA b), is indicated
for treating patients with moderately to severely active ulcerative colitis (UC) and Crohn's …